3.27
+0.21(+6.86%)
Currency In USD
| Previous Close | 3.06 |
| Open | 3.05 |
| Day High | 3.38 |
| Day Low | 3.05 |
| 52-Week High | 19.34 |
| 52-Week Low | 2.66 |
| Volume | 295,598 |
| Average Volume | 339,145 |
| Market Cap | 89.38M |
| PE | -0.03 |
| EPS | -122.52 |
| Moving Average 50 Days | 4.15 |
| Moving Average 200 Days | 7.45 |
| Change | 0.21 |
If you invested $1000 in 23andMe Holding Co. (ME) since IPO date, it would be worth $16.68 as of December 21, 2024 at a share price of $3.27. Whereas If you bought $1000 worth of 23andMe Holding Co. (ME) shares 3 years ago, it would be worth $23.83 as of December 21, 2024 at a share price of $3.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
GlobeNewswire Inc.
Nov 20, 2024 12:30 PM GMT
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developin
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
GlobeNewswire Inc.
Nov 12, 2024 12:30 PM GMT
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 3
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
GlobeNewswire Inc.
Nov 11, 2024 10:30 PM GMT
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs SUNNYVALE, Calif., Nov. 1